Maybe. There are two other milestones prior to end of July provided FDA issue minutes within 30 days. Minutes for last FDA meeting (due either 1st or 2nd week July) from which MSB will be able to detail the timing. Secondly, Adult GVHD meeting with FDA in early July. Certainly the first event IS market sensitive and could not wait the 2-3 weeks for the quarterly to be submitted. This will need an immediate announcement. As this has a major impact on the timing for accelerated approval pathway for Revascor defining if we are still looking at mid 2026 or not. So it might only be 2-3 weeks to get an update on heart AA and maybe a read from second FDA meeting re Adult GVHD if there was "general agreement" to progress. These announcements could significantly move the pricing. Agree, as per the last announcement there will be no sales update until the quarterly.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)